Clinical Trials · NCT04484818
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Enrollment
- 27
- Start date
- Mar 2021
- Locations
- 115 sites, United States
- Primary endpoint
- Metastasis-free survival (MFS)